Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,333 across all filing types
Latest filing 2015-08-06 Report Publication Anno…
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Correction - Photocure ASA: Presentation of the second quarter and first half-year 2015 results
Report Publication Announcement Classification · 99% confidence The document is a correction notice announcing the date and time for the presentation of the company's 'second quarter and first half-year 2015 results'. It details the schedule for the presentation, including Q&A, webcast links, and dial-in information for an audio conference call. This structure—announcing the release of periodic results and providing access details for investors—is characteristic of an Earnings Release (ER) or a related event announcement. Since it specifically mentions the presentation of quarterly/half-year results and provides conference call details, it strongly aligns with the intent of an Earnings Release (ER), even though it is technically an announcement about the presentation itself. Given the options, ER is the most appropriate fit for an announcement detailing the schedule for presenting periodic financial results.
2015-08-06 English
Photocure ASA: Presentation of the second quarter and first half-year 2015 results
Report Publication Announcement Classification · 95% confidence The document explicitly states it is a 'Presentation of the second quarter and first half-year 2015 results' and provides details about when and where this presentation will occur (date, time, location, webcast links, and Q&A call details). This is an announcement about an upcoming event where results will be presented, rather than the full report (IR) or the transcript of the call (CT). Since it is an announcement detailing the release/presentation of results, it fits best under Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports.
2015-08-06 English
Photocure ASA: Share capital increase registered
Share Issue/Capital Change Classification · 98% confidence The document explicitly states 'Share capital increase registered' and details the resulting change in the number of shares and the total registered share capital (NOK 10,712,732.50 divided on 21,425,465 shares). This directly relates to a change in the company's capital structure due to the exercise of employee share options. This aligns perfectly with the definition of 'Share Issue/Capital Change' (Code: SHA). It is not a general regulatory filing (RNS) because it fits a specific category, nor is it a financing update (CAP) which usually implies raising external capital, but rather an internal capital structure adjustment.
2015-06-04 English
Photocure ASA: Renewal of market maker agreement
Regulatory Filings Classification · 100% confidence The document is very short (731 characters) and announces a change in the company's market maker agreement (a procedural/administrative update regarding stock liquidity). It does not contain detailed financial results (ruling out 10-K, IR, ER), management changes (MANG), or shareholder voting information (AGM-R, DVA). Since it is a specific, non-financial administrative announcement that doesn't fit the other specific categories (like DIRS, DIV, CAP, etc.), it best fits the general regulatory announcement fallback category, RNS, as it is a disclosure required under securities law (§5-12 vphl).
2015-05-26 English
PHOTOCURE ANNOUNCES EXCLUSIVE PARTNER FOR HEXVIX® IN AUSTRALIA AND NEW ZEALAND
Regulatory Filings Classification · 100% confidence The document is a press release dated May 22, 2015, announcing an exclusive distribution agreement between Photocure ASA and Juno Pharmaceuticals for Hexvix in Australia and New Zealand. This type of announcement, detailing a commercial partnership, milestone payments, and regulatory filing plans by a specialty pharmaceutical company, does not fit the specific definitions for 10-K, ER, IR, or AGM materials. It is a general corporate announcement regarding business development. Since it is not a report itself, nor a specific filing like DIRS or DIV, the most appropriate general category for a significant business update that isn't a standard financial report or a specific corporate action filing is Regulatory Filings (RNS), as it is a formal announcement to the market, often required by listing rules (as hinted by the final line referencing disclosure requirements). However, given the content is a strategic business deal announcement, it is often classified under a general 'News Release' or 'Corporate Update' category. Among the provided options, RNS serves as the best general regulatory announcement fallback, although it is not a perfect fit for a pure M&A/Partnership announcement (TAR is for M&A/Takeovers). Since this is a partnership announcement, and RNS is the general regulatory filing catch-all, I will use RNS, as it is a formal market disclosure.
2015-05-22 English
Photocure ASA: Resolved share capital increase in connection with exercise of options
Share Issue/Capital Change Classification · 99% confidence The document explicitly states that the board of directors resolved a 'share capital increase' due to employees exercising vested options, resulting in the issuance of 32,164 new shares. This directly relates to a change in the company's capital structure through the issuance of new shares. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). It is not a general announcement of a report (RPA/RNS) because it contains the substantive details of the capital change itself, nor is it a general financing update (CAP) which is broader.
2015-05-12 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.